SLFN5 as a dual-function oncogene and immune regulator: A pan-cancer multi-omics analysis linking prognosis, immune evasion, and therapeutic vulnerability

Fubiao Kang, Ziye Yang, Dong Li, Delong Lv, Peihua Su, Yan Wang, Lianli Zhang

Open source

DOI
10.1016/j.ctarc.2026.101145
Published
2026
Container
Cancer Treatment and Research Communications
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ctarc.2026.101145,
  title = {SLFN5 as a dual-function oncogene and immune regulator: A pan-cancer multi-omics analysis linking prognosis, immune evasion, and therapeutic vulnerability},
  author = {Fubiao Kang and Ziye Yang and Dong Li and Delong Lv and Peihua Su and Yan Wang and Lianli Zhang},
  year = {2026},
  journal = {Cancer Treatment and Research Communications},
  doi = {10.1016/j.ctarc.2026.101145},
  url = {https://doi.org/10.1016/j.ctarc.2026.101145}
}

RIS

TY  - JOUR
TI  - SLFN5 as a dual-function oncogene and immune regulator: A pan-cancer multi-omics analysis linking prognosis, immune evasion, and therapeutic vulnerability
AU  - Fubiao Kang
AU  - Ziye Yang
AU  - Dong Li
AU  - Delong Lv
AU  - Peihua Su
AU  - Yan Wang
AU  - Lianli Zhang
PY  - 2026
JO  - Cancer Treatment and Research Communications
DO  - 10.1016/j.ctarc.2026.101145
UR  - https://doi.org/10.1016/j.ctarc.2026.101145
ER  - 

APA

Kang, F., Yang, Z., Li, D., Lv, D., Su, P., Wang, Y., & Zhang, L. (2026). SLFN5 as a dual-function oncogene and immune regulator: A pan-cancer multi-omics analysis linking prognosis, immune evasion, and therapeutic vulnerability. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101145

Source records